Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia

2022-05-17T13:11:57+01:00

Serious and life-threatening hypercalcaemia has been reported with denosumab 60mg (Prolia) in children and adolescents in clinical trials for osteogenesis imperfecta and during off-label use. Denosumab 60mg (Prolia) is autho…